Evidence map›Paper›PMID 39921567›Full record

ArticleNucleic acids research2025

Elevated reactive oxygen species can drive the alternative lengthening of telomeres pathway in ATRX-null cancers.

Tomas Goncalves, Siobhan Cunniffe, Tiffany S Ma, Natalie Mattis, Andrew W Rose, Thomas Kent, David R Mole, Helene E B Geiller, Linda van Bijsterveldt, Timothy C Humphrey and 4 more

Abstract read
In one paragraph

Article in Nucleic acids research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Tomas GoncalvesMRC Molecular Haematology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, OX3 9DS, UK.
Siobhan CunniffeDepartment of Oncology, University of Oxford, Oxford, OX3 7DQ, UK.
Tiffany S MaDepartment of Oncology, University of Oxford, Oxford, OX3 7DQ, UK.
Natalie MattisDepartment of Paediatrics, University of Oxford, Oxford, OX3 9DU, UK.
Andrew W RoseDepartment of Physics, Faculty of Natural Sciences, Imperial College, London, SW7 2BW, UK.
Thomas KentMRC Molecular Haematology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, OX3 9DS, UK.
David R MoleNuffield Department of Medicine, University of Oxford, Oxford, OX3 7BN, UK.
Helene E B GeillerDepartment of Oncology, University of Oxford, Oxford, OX3 7DQ, UK.
Linda van BijsterveldtDepartment of Oncology, University of Oxford, Oxford, OX3 7DQ, UK.
Timothy C HumphreyDepartment of Oncology, University of Oxford, Oxford, OX3 7DQ, UK.ORCID 0000-0002-2254-9198
Ester M HammondDepartment of Oncology, University of Oxford, Oxford, OX3 7DQ, UK.ORCID 0000-0002-2335-3146
Richard J GibbonsMRC Molecular Haematology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, OX3 9DS, UK.
David ClynesDepartment of Oncology, University of Oxford, Oxford, OX3 7DQ, UK.
Anna M RoseMRC Molecular Haematology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, OX3 9DS, UK.ORCID 0000-0001-9737-6925

Funding

Academy of Medical Sciences Starter SGL023\1055Cancer Research UK C6078/A28736Children with Cancer UK 15-202EU Horizon Europe Research and Innovation program Cancer Mission 'HIT-GLIO' 101 136 835HSRD VA CDP 13-005MRC DPhil StudentshipNational Institute of Health and Care Research Clinical Lectureship CL-2018-13-005University of Oxford Medical Sciences 0 011 483
6 · The paper itself

Abstract

The alternative lengthening of telomeres (ALT) pathway is a telomerase-independent mechanism for immortalization in cancer cells and is commonly activated in low-grade and high-grade glioma, as well as osteosarcoma. The ALT pathway can be activated under various conditions and has often been shown to include mutational loss of ATRX. However, this is insufficient in isolation and so other cellular event must also be implicated. It has been shown that excessive accumulation of DNA:RNA hybrid structures (R-loops) and/or formation of DNA-protein crosslinks (DPCs) can be other important driving factors. The underlying cellular events leading to R-loop and DPC formation in ALT cancer cells to date remain unclear. Here, we demonstrate that excessive cellular reactive oxygen species (ROS) is an important causative factor in the evolution of ALT-telomere maintenance in ATRX-deficient glioma. We identified three sources of elevated ROS in ALT-positive gliomas: co-mutation of SETD2, downregulation of DRG2, and hypoxic tumour microenvironment. We demonstrate that elevated ROS leads to accumulation of R-loops and, crucially, resolution of R-loops by the enzyme RNase H1 prevents ALT pathway activity in cells exposed to elevated ROS. Further, we found a possible causal link between the formation of R-loops and the accumulation of DPCs, in particular, formation of TOP1 complexes covalently linked to DNA (Top1cc). We also demonstrate that elevation of ROS can trigger over-activity of the ALT pathway in osteosarcoma and glioma cell lines, resulting in excessive DNA damage and cell death. This work presents important mechanistic insights into the endogenous origin of excessive R-loops and DPCs in ALT-positive cancers, as well as highlighting potential novel therapeutic approaches in these difficult-to-treat cancer types.

Indexed as

GliomaReactive Oxygen SpeciesTelomereTelomere HomeostasisX-linked Nuclear ProteinCell Line, TumorHistone-Lysine N-MethyltransferaseHumansMutationR-Loop StructuresTumor MicroenvironmentATRX protein, humanHistone-Lysine N-MethyltransferaseReactive Oxygen SpeciesX-linked Nuclear Protein

Identifiers

PMID39921567
PMCPMC11806356

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.